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Similar to bile duct cancer or cholangiocarcinoma (CCA) in the western world, opisthorchiasis- 
associated CCA in Southeast Asia is an aggressive cancer with high mortality rates. It 
is known to cause a significant health burden in the opisthorchiasis region in Thailand 
and possibly throughout mainland Southeast. To reduce this health burden, a compre-
hensive prevention and control program for opisthorchiasis, as well as CCA, is required. 
In this review, our aim is to provide a brief update of the current situation regarding the 
natural history of opisthorchiasis and health burden of CCA in Southeast Asia. A com-
prehensive approach to tackling these issues being implemented in Thailand under the 
“Cholangiocarcinoma Screening and Care Program” is described. This comprehensive 
program consists of a three stage prevention and patient care program. The primary 
prevention component involves opisthorchiasis screening using a new and sensitive 
urine assay. The secondary prevention component involves screening for CCA and peri-
ductal fibrosis, with suspected CCA patients following the protocol for confirmation and 
appropriate treatment. Due to the eco-epidemiology of opisthorchiasis-induced CCA, 
the anticipated impacts and outcomes of the program include short-, medium-, and the 
long-term goals for the reduction of CCA incidence. To achieve long-term sustainable 
impacts, concerted efforts to raise social awareness and participating action by general 
public, non-government organizations, and government agencies are necessary. The 
strategic plans developed for this program can be expanded for use in other endemic 
areas as well as being a model for use in other chronic diseases.
Keywords: Opisthorchis viverrini, cholangiocarcinoma, screening, primary prevention, secondary prevention, 
tertiary care program
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iNTRODUCTiON
The liver fluke, Opisthorchis viverrini, was recognized as a para­
site of humans early last century; however, its role in causing 
cholangiocarcinoma (CCA) was officially recognized in 1994. It 
is one of three trematode species, the others being Schistosoma 
haematobium and Clonorchis sinensis, that are classified as group 
1 carcinogenic parasites (1).
Our aim here is to provide a brief update of the current situa­
tion relating to opisthorchiasis and CCA in Southeast Asia and to 
discuss a comprehensive approach to tackling issues from primary 
and secondary to tertiary patient care based on a program that 
is being implemented in Thailand. Due to the eco­epidemiology 
of opisthorchiasis­induced CCA, the anticipated impacts and 
outcomes of the program include short­, medium­, and the 
long­term goals for the reduction of CCA incidence. To achieve 
such long­term, sustainable impacts, concerted efforts by general 
public, non­government organizations, and government agencies 
are required. This review consists of three main sections starting 
with a current update of opisthorchiasis and CCA, followed by 
intervention and solution, anticipated outcomes and long­term 
goals, and then conclusion and the future goals. As a case study, 
the comprehensive prevention and control program being 
conducted in Thailand will be illustrated. Finally the anticipated 
outcomes will be discussed in terms of the success, maintenance, 
and sustainability of the program. More details for specific issues 
regarding the natural history of opisthorchiasis and CCA can be 
found in some recent publications (2–5).
CURReNT SiTUATiON
Distribution and Life Cycle of O. viverrini
Substantial molecular and biological data exists showing that 
O. viverrini is a complex of morphologically similar species (6–8). 
O. viverrini sensu lato is found in those countries bordering the 
Lower Mekong River in continental Southeast Asia. It appears 
to be most frequent in Lao PDR, the north and northeast of 
Thailand, parts of Cambodia, and southern Vietnam (9), with a 
recent first record from Myanmar (10). Evidence suggests that its 
range is restricted to areas occupied by its first intermediate hosts, 
freshwater Bithynia snails (11) (Figure 1).
Opisthorchis viverrini has a complex life cycle in which eggs are 
excreted in the feces of the final hosts, usually humans, with cats 
and more rarely dogs also acting in this role (6, 12). The eggs are 
ingested, probably together with fecal matter, by freshwater snails 
that act as first intermediate hosts. To date, three snail taxa Bithynia 
funiculata, Bithynia siamensis siamensis, and Bithynia s. goniom­
phalos are known hosts, although molecular evidence suggests 
that B. s. siamensis and B. s. goniomphalos are full species within 
extensive species complexes (13). Eggs hatch in snails undergo­
ing a phase of asexual reproduction before exiting as cercariae. 
They actively seek a cyprinid fish as second intermediate host 
developing to metacercariae that are infective to humans who eat 
uncooked or undercooked fish. Eating raw or mildly fermented 
fish is a traditional practice in the countries where O. viverrini  
is endemic (14). Once in the final host, the metacercariae develop 
to hermaphrodite adult worms and move into the biliary tract, 
attach to the epithelium, feed on host secretions, mate and lay 
eggs (15). Adult worms produce 50–200 eggs/g feces/day for 
many years (16).
Molecular Biology and Systematics  
of O. viverrini
Molecular biology and systematics investigations of medically 
important trematodes, including the liver fluke O. viverrini, 
have used increasingly sophisticated methodologies that have 
increased our understanding of host–parasite interactions and 
the mechanisms of disease pathogenesis. Importantly, they pro­
vide a foundation to develop/establish new diagnostic methods, 
drug treatments, and effective vaccines. In addition, they enhance 
our understanding of the carcinogenesis process (17). Molecular 
studies have focused specifically on characterizing the O. viverrini 
protein tegument and excretion–secretion products, which can 
provide defined molecular targets to treat infection, facilitate the 
development of new, rapid/cheap diagnostic tools which could 
break the transmission cycle, and potentially identify targets for 
vaccine development (7).
Since the first report of liver fluke infection in prisoners in 
northern Thailand (18), only one species, O. viverrini has been 
recognized by morphology and geographical distribution (9, 15). 
A groundbreaking molecular genetic study by Saijuntha et al. (19) 
revolutionized O. viverrini systematics with the discovery that it is 
a species complex “O. viverrini sensu lato (sl)” (hereafter referred 
to as OV) containing two evolutionary lineages with many cryptic 
species (morphologically similar but genetically distinct) occur­
ring in distinct wetlands in Thailand and Lao PDR. Furthermore, 
there is evidence of potential co­evolution between OV and its 
first intermediate host, Bithynia snails (13).
Since 2007, molecular genetic studies (RAPD, microsatel­
lite, DNA, and RNA) have provided independent evidence 
for two genetically distinct evolutionary lineages existing in 
Thailand and Lao PDR, each of which contains many cryptic 
species with high genetic variability within and between dif­
ferent populations associated with different geographical areas, 
temporal factors, and fish host species (20–25). Apart from 
geographical factors associated with the genetic differentiation 
of OV populations, temporal and host interactions also have an 
effect on genetic variation, for instance, temporal factors and 
different fish species affect OV population genetics (21, 26). 
Furthermore, these studies showed that self­fertilization and/or 
a clonal distribution commonly occurs in populations/cryptic 
species. A recent molecular study (27) suggested that geographi­
cal separation is more important than fish host specificity in 
influencing OV genetic structure. Further studies should 
examine host selection for OV in Bithynia snails from different 
populations within each cryptic species, as they are the critical 
parasite amplifying stage. Furthermore, extensive molecular 
genetic studies are required to define the systematics and popu­
lation structure of OV throughout continental Southeast Asia 
(6). An accurate understanding of the molecular biology and 
systematics of OV is essential for the prevention and control of 
infection and provides valuable information for early effective 
FigURe 1 | Distribution of Opisthorchis viverrini (OV) in Southeast Asia.
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diagnosis and treatment of CCA, hence, reducing mortality 
rates in endemic areas (6, 8).
Diagnosis and Screening  
of Opisthorchiasis
The conventional diagnostic method for human fish­borne 
trematodes, including OV, is searching for eggs in fecal samples. 
Several methods have been used successfully in the past, such 
as the modified formalin ether concentration technique (28), 
the modified thick Kato smear (29), and Stoll’s dilution egg 
count technique (30). The reliability of fecal examination was 
determined from an autopsy study that revealed many infected 
individuals with low infection intensities and limited egg out­
put leading to an under diagnosis by as much as 20% (31). In 
addition to low infection intensities, intermittent egg excretion 
and bile duct obstruction due to chronic infection or cholan­
giocarcinogenesis all undermine the sensitivity of conventional 
stool examinations (32). Another diagnostic problem is the 
concurrent transmission of OV with several species of fish­borne 
zoonotic trematode belonging to the families Heterophyidae 
and Lecithodendriidae, referred to as minute intestinal flukes 
4Khuntikeo et al. Asian Opisthorchiasis and CCA
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(MIF) (33–35). MIF eggs have a similar size and shape to the 
liver flukes eggs potentially causing false positive diagnoses, and 
reducing diagnostic specificity (15, 33). Molecular diagnosis of 
opisthorchiasis by PCR targeting at repeat DNA element offered 
high specificity but variable sensitivity (36–41). Loop­mediated 
isothermal amplification (LAMP) has been established for the 
detection of both OV and C. sinensis with a higher sensitivity 
than conventional PCR (42–44). Species­specific PCRs are now 
also available to distinguish between different liver fluke species: 
OV (40), Opisthorchis felineus (45) and C. sinensis (46). Molecular 
methods discussed earlier will contribute significantly toward a 
more effective and accurate diagnosis of trematode infections. 
Further simplification of the tests and an understanding of cost 
effectiveness under various socioeconomic scenarios are needed.
Alternatively, several serological antibody tests for opisthor­
chiasis and clonorchiasis have been developed as diagnostic 
assays with greater sensitivity and specificity than fecal examina­
tion. These include the intradermal test, immunoelectrophoresis, 
indirect hemagglutination assay, indirect fluorescent antibody 
test and indirect enzyme­linked immunosorbent assay (indirect 
ELISA) (39, 47). Indirect ELISA is preferred for the detection 
of antibodies using different types of antigen including crude 
somatic extracts of adult worms (48, 49) and excretory­secretory 
antigens (50, 51). These are superior to fecal examination. The 
detection of parasite­specific antibodies in other clinical samples, 
such as urine and saliva, is possible and offers the potential for 
the serodiagnosis of opisthorchiasis, and these antibodies could 
act as markers for associated morbidities (52–55). To increase 
diagnostic performance and reduce the cross reactivity of parasite 
proteins, several recombinant antigens from eggs and worms 
were produced and tested (56–59). However, our inability to 
discriminate current and past infections poses the main problem 
for serological antibody diagnosis (47).
To avoid the drawback of antibody­based detection, secretory 
products from adult worms could be used to indicate a current 
infection (60–62). In this regard, monoclonal antibody­based 
systems offer increased diagnostic sensitivity, as they discover 
infections when eggs are not detectable in fecal samples (61), as 
corroborated in an autopsy study (31). Currently, both copro and 
urine antigen detection are possible for opisthorchiasis, with the 
advantage of antigen detection when fecal examination for eggs is 
negative (63, 64). The antigen concentration measured is also cor­
related with the intensity of infection. Due to its simplicity and the 
non­invasive nature of sample collection, the urine antigen assay 
provides a better alternative diagnostic method to conventional 
fecal examination and has revolutionized the diagnostic approach 
of opisthorchiasis. The urine assay is being applied for large­scale 
population screening. It has become the method of choice in the 
control program in Thailand. Based on its diagnostic potential, a 
test strip in the form of the point of care test is now being deve­
loped and produced for large­scale use in endemic areas.
Pathogenesis of Opisthorchiasis  
and Cholangiocarcinogenesis
Chronic infection and persistent inflammation are recognized 
as important risk factors in many human cancers; emerging 
evidence suggests that cancer­related inflammatory processes 
cause genetic instability and are involved in initiation, promo­
tion, and progression of carcinogenesis (65). Opisthorchiasis, 
particularly repeated infections, causes chronic inflammation 
via pro­inflammatory cytokines (i.e., IL­6) and transcription 
factor NF­κB that induce oxidative stress response enzymes 
generating reactive oxygen and nitrogen species (ROS and 
RNS). The resulting persistent oxidative/nitrative stress disturbs 
the homeostasis of many adaptive response systems such as the 
oxidant/antioxidant ratio, DNA repair enzymes including many 
altered candidate genes involved in controlling cell prolifera­
tion, apoptosis, and fibrogenesis. Overproduction of ROS and 
RNS leads to genotoxic DNA damage as evidenced by the high 
level of 8­oxodG, 8­nitroguanine, and etheno­DNA adducts 
(εdA and εdC) detected in affected tissues. Excess ROS and 
RNS can also increase endogenous nitrosation reactions to 
yield carcinogenic N­nitrosamines such as NDMA that alkylate 
DNA bases. All these events may act as driving forces leading 
to cholangiocarcinogenesis. This has been intensively reviewed 
by Yongvanit et al. (66) and Thanan et al. (67). Some of these 
molecules (i.e., oxidized alpha 1­antitrypsin, 8­oxodG, etc.) are 
potential biomarkers for opisthorchiasis­associated periductal 
fibrosis and CCA (53, 68–71). However, reliable and specific 
biomarker(s) for opisthorchiasis­associated CCA remain to be 
determined.
Health Burden, Morbidity, and Mortality
Cholangiocarcinoma is an uncommon cancer in most parts of 
the world, where incidences are usually lower than 2/100,000 
cases/year (72). However, in areas where liver flukes are common 
parasites infecting humans, the incidence of CCA is much higher. 
Indeed, the highest worldwide are found in north and northeast 
Thailand, reaching between 98.8 and 317.6/100,000/year at ages 
above 35 years depending on the district examined (73). Accurate 
data from the other Southeast Asian countries where this parasite 
occurs are inadequate for determining the frequency of disease 
occurrence, although high prevalences of OV infection have been 
noted in parts of Lao PDR and Cambodia (74–77).
Infection with OV is mostly asymptomatic but can cause 
morbidity if the worm burden is high. In this case, symptoms 
may include right upper quadrant abdominal pain, flatulence, 
fatigue, and mild hepatomegaly (78). In very heavy infections, 
attached adult worms in the biliary tract can cause epithelial 
hyperplasia and potentially biliary obstruction leading to 
cholangitis, obstructive jaundice, periductal fibrosis, and 
enlargement of the gall bladder (79–81). If treated before CCA 
emergence, OV infection is usually of relatively minor medical 
significance and can be cured by use of the anthelmintic drug 
praziquantel.
Early stage CCA is largely asymptomatic, so that patients pre­
senting at a hospital usually have late stage disease with no cura­
tive option (82–84). CCA is by far the most common liver cancer 
in Thailand (85, 86), where it is the fifth most common cause 
of death in males and the eighth in females (87). Postmortem, 
a major burden falls on the family as death usually occurs in 
males in the 40–65 age group working in agriculture (88), 
i.e., individuals from relatively poor families who are breadwinners. 
FigURe 3 | Ultrasound image and compute tomography in cholan-
giocarcinoma (CCA). (A) Ultrasound image shows a mild degree of  
dilatation of the intrahepatic bile duct left lobe of the liver (black arrows).  
(B) Portal phase computed tomography shows infiltrative tumor along left 
hepatic duct (white arrow) with dilatation of intrahepatic duct in left lobe 
(black arrow). Final diagnosis is perihilar periductal CCA stage II  
(AJCC 7th edition).
FigURe 2 | Opisthorchiasis-associated cholangiocarcinoma.  
(A) Cholangiocarcinoma specimen showing adult worms in the bile duct  
(blue arrows). (B) Adult Opisthorchis viverrini recovered from the liver.
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An example of CCA patient who harbored live adult O. viverrini 
was illustrated in Figures 2 and 3.
iNTeRveNTiON AND SOLUTiON
The Cholangiocarcinoma Screening  
and Care Program (CASCAP)
The CASCAP is a package with different levels of activities (Table 1). 
It consists of a primary control program targeting the prevention 
and control of opisthorchiasis. The ultrasound screening (US) for 
hepatobiliary disease including CCA serves as a secondary control 
program in which at risk population is systematically recruited 
for screening. Suspected patients are then sent for confirmatory 
diagnosis, treatment, and care in a tertiary control program.
The Primary Prevention Program: Food 
Safety, School-Based Health education, 
and Screening of O. viverrini
The primary prevention program involves a campaign for food 
safety education and an improved strategy for opisthorchiasis 
screening and treatment based on the urine assay. For the long­
term vision, school­based curricula dealing with OV and CCA 
were initiated.
Because cyprinid fish are the source of infection, the primary 
preventive effort is to stop raw or insufficiently cooked fish being 
eaten. Food safety is the key issue for the control of opisthorchiasis, 
but this is difficult to reduce or stop the consumption if infective 
fish products as these have a long­standing tradition as key food 
items in the affected areas (14). Previous reports indicated that 
TABLe 1 | The missions of Cholangiocarcinoma Screening and Care Program 
and strategy to achieve specific goals.
Mission Strategy/tool goal
Primary prevention – Identify the current source 
of OV infection
– New urine assay for 
diagnosis of opisthorchiasis
– School-based curricula
– Block transmission
– Effective 
screening and 
chemotherapeutic 
control of OV
– Fluke-free generation
Secondary prevention – Ultrasound screening of at 
risk individuals
– Early case detection 
and referral
Tertiary prevention – Treatment
– Palliative care
– Curative treatment 
and therapy
Isan Cohort – Data center and 
management with ethical 
standards
– Public data base for 
disease control
Cholangiocarcinoma 
Foundation
– Raise funds to stimulate 
and support prevention and 
engage in public advocacy 
at all levels
 – High social/public 
awareness of OV and 
CCA
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OV is still prevalent in different forms of fermented fish dishes in 
northeast Thailand (89) and “Pla som,” a short­term fermented 
cyprinid fish dish (3–4  days at ambient temperature) can con­
tain viable metacercariae (89). This recent finding supports the 
hypothesis that Pla som is likely an important source of infection.
School­based health education has been advocated for preven­
tion of many infectious diseases (90) as well as for OV and CCA 
(91). Based on our initial trial (92), a school­based curricula 
program was established through the Faculty of Education, Khon 
Kaen University (KKU), and included primary to second­
ary school courses as well as vocational study. This has been 
implemented in 31 schools in 3 provinces in northeast Thailand. 
Selected schools were located in active OV transmission in the 
Chi, Mun and Songkhram River wetlands, and the program spans 
3 years with formal educational evaluation as well as the impact 
on OV infection.
The CASCAP screening program is being operated as a Thai 
Ministry of Public Health (MOPH) national program, from 2015 to 
2026, as part of the national policy to control of opisthorchiasis and 
CCA. In 2015, the targeted population screened by fecal examination 
(Kato­thick smear) involved 76,000 people in 84 sub­districts in 27 
provinces in the north, northeast, and central Thailand. The urine 
assay based from our previous work (64) is being applied in opisthor­
chiasis region nationwide to evaluate the current OV prevalence. It is 
anticipated that by using a more sensitive urine assay, the true preva­
lence of opisthorchiasis and its current distribution can be revealed. 
In addition, reinfection and new infections can be evaluated. Thus, 
the frequency of treatment can be planed for parasite control and 
eventually eliminate the parasite in the community.
Secondary Prevention Program:  
US for CCA
Most patients presenting at a hospital have late stage disease with 
palliative care being the most common treatment option. Thus, 
there is a second, undetected group that has early stage CCA 
without being aware of it (88). If, however, these individuals with 
early stage disease can be found, then curative surgery is possible 
(93). To find these individuals, CASCAP was initiated (83, 88). 
Given that an estimated six million people in Thailand fall within 
threat risk group (age over 40, with a history of OV infection, 
eating raw or fermented fish, and/or relatives with CCA), the 
screening program is a massive undertaking.
Screening by US is a suitable method for the initial diagnosis 
of CCA, as well as for periductal fibrosis, which is a potential 
precursor of this cancer (94). The screening program started 
with the recruitment of at risk individuals who had previously 
registered at a sub­district health clinic. US examination takes 
place at local medical facilities (clinics and hospitals) or through 
the CASCAP mobile unit, which can examine 500 individuals a 
day. Screening divides the patients into four groups: (1) without 
liver pathology, (2) with liver pathology not directly related to 
CCA (e.g., fatty liver or cirrhosis), (3) with periductal fibrosis as 
a potential precursor of CCA, and (4) with suspected CCA (liver 
mass and bile duct dilatation). Patients with no pathology are 
asked to return for control in about a year, those with significant 
pathology not related to CCA are referred to a local hospital, those 
with periductal fibrosis are asked to return after 6 months for a 
control examination and those with suspected CCA are referred 
for further diagnostic tests.
A teleconsultation system, via the CASCAP Cloud software, is 
coupled with the US examination, allowing diagnostic confirma­
tion by a specialized radiologist at a tertiary hospital (95). Digital 
images from the US examination are transferred to and stored on 
the Cloud system for future reference (88). The cohort studies will 
aid in the discovery of biomarkers for CCA and potentially speed 
up the process of screening.
Tertiary Patient Care Program: 
Confirmation and Management  
of Suspected CCA
Ultrasound screening has had a major impact on active, early 
stage CCA detection and the subsequent treatment of patients, 
saving many lives. The initial results can be seen among the cohort 
that underwent screening, with a confirmed diagnosis of CCA. 
Among 54 patients with histopathologically confirmed CCA, 
the staging was 0–2 (72.5%) and 3–4 (27.5%). By contrast, in the 
walk­in cohort of 506 surgical cases (at Outpatient Departments), 
histopathological staging was 0–2 (29%) and 3–4 (71%). Although 
data confirmation is still required, this reverse trend from late to 
early stage CCA detected in the CASCAP program is a positive 
sign toward the eventual curative treatment and reduction of CCA.
The CCA Center of Excellence was established as a national, 
regional and international hub at Srinagarind Hospital, KKU. 
This contains 5 dedicated facilities: (1) a CCA ward (19 beds), 
(2) 1 operating theater, (3) an intensive care unit of 2 beds, 
(4) a bio­bank, and (5) research laboratories. This forms the 
basis for establishing five specialist CCA functions, namely, for 
tertiary referral, training, research, networking, and a national, 
regional, and international focal point. Currently, all five func­
tions have reached their goals and are developing at a good 
level. Furthermore, a multidisciplinary CCA patient care team 
TABLe 2 | Number and percentage of ultrasonography diagnoses (n = 421,895).
Ultrasonography findings No. %
Normal liver 259,465 61.5
Abnormal liver 162,429 38.5
Fatty liver (combined grading) 83,102 19.7
Periductal fibrosis 73,303 17.4
Cirrhosis 2,279 0.5
Parenchymal change of liver 5,809 1.4
Liver mass 4,601 1.1
Bile duct dilated 4,999 1.2
Suspected CCA 4,358 1.0
Gall stone 16,303 3.9
Renal cyst 14,639 3.5
Renal stone 11,906 2.8
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has been established to improve the quality of CCA care, which 
includes nurses, medical oncologists, hepatobiliary­pancreatic 
(HBP) surgeons, radiologists, pathologists, and radiotherapists. 
This provides avenues for a better understanding and effective 
dissemination of information, as well as for acquiring specialist 
skills at all levels to combat CCA.
To strengthen both screening and surgical capacity, capacity 
building and networking to cope with increasing number of 
CCA patients is needed. Two training programs were estab­
lished to enhance screening and care. A Training Program in 
Cholangiocarcinoma US Screening for Radiologists and General 
Practitioners was initiated to provide radiologists and general 
practitioners with the knowledge, skills, and expertise to diagnose 
CCA using US. This training program operates every 2 months. 
More than 60 radiologists have passed the training program and 
can further train GPs and consult with GPs via teleconsultation 
(95). A total of 789 medical doctors from provincial and district 
hospitals throughout the country were trained to January 2018.
In Thailand, there are an estimated 20,000 CCA cases/year. 
Considering a single hospital, Srinagarind Hospital, unfortunately 
only about 10% of those affected (ca. 200 of 2,000) finally reached 
the hospital where they received appropriate treatment and pallia­
tive care (84). To increase the capability of the health­care system, 
particularly the provincial hospitals, improvement and expansion 
of facilities and personnel are inevitable. In particular, HBP surgeon 
training is a priority. Thus, a Training Program in Hepatobiliary 
and Pancreatic Surgery was initiated and is currently offered by the 
Department of Surgery, Faculty of Medicine, KKU. The objective is 
to provide trained surgeons with knowledge, skills, and expertise in 
the field of surgical diseases of the liver, biliary tract, and pancreas. 
This is a 1­year course, and up to eight HBP surgeons can be trained 
for work in north and northeast Thailand. The partner hospitals for 
surgical training included Khon Kaen, Sunpasitthiprasong, Surin 
Hospitals, and National Cancer Institute in Bangkok. In addition 
to the HBP training, special financial support from NGOs and 
charity organizations has been implemented to help increase the 
number of surgical treatments, i.e., 500 cases/year, within these 
network hospitals.
Database Facility: isan Cohort
The Isan Cohort is a web application located at www.cascap.
in.th. This application uses the CASCAP protocol in an internet 
platform so that health­care institutes across Thailand can use it 
in a systematic, unified, single approach. The name “Isan” (the 
northeastern region of Thailand) is known to have the highest 
rate of CCA worldwide. The protocol started with the enrollment 
of at risk individuals. This created two initial cohorts: the OV 
Screening Cohort and the CCA Screening Cohort. Cohort mem­
bers undergo the OV test followed by hepatobiliary US. Baseline 
demographic information and risk factors were recorded during 
enrollment, and screening results were recorded at US. If positive 
findings were detected, the OV Screening Cohort received prazi­
quantel, while CCA Screening group patients were transferred 
for advanced diagnosis using CT/MRI. If confirmed, participants 
moved to the Patient Cohort. Information collected during 
these processes was recorded on case report forms designed by 
CASCAP.
In January 2018, there were 3,713 health­care centers vol­
untarily participated in the Isan Cohort study. Of these, 33 were 
tertiary hospitals, and 354 were community hospitals equating to 
44% (387/881) of all hospitals in Thailand. The remaining 3,326 
were health­care centers. Each center applied for an account at 
Isan Cohort where the Isan Cohort generated a new database and 
assigned to a Uniform Resource Locator (URL) specifically for 
each center. The URL took the name of the institute in place of the 
www part of the Isan Cohort URL. Hence, Isan Cohort become 
the central “parent” site with an unlimited number of “daughter” 
sites so that privacy within each institute remained preserved even 
though health­care information exchange (HIE) was possible.
Second, the institutes can transfer health information in 
their own health information system (HIS) to Isan Cohort auto­
matically in real time. This can be done by installing the Thai 
Database Connector (TDC) in their replicated HIS servers. The 
TDC triggers algorithms that can transfer required data that are 
encrypted in the Isan Cohort server. This is done automatically 
once the data are entered into HIS. Thus, work is not replicated, 
allowing HIE without borders. In addition, this approach ensures 
sustainability of the Isan Cohort even if there is limited financial 
support because stored health information can be updated without 
any additional effort as long as the institutes remain members 
of Isan Cohort. To date, 23,618,285 individuals have the health 
information required by CASCAP archived at Isan Cohort. 
Of these, the member institutes enrolled have 1,406,216 individ uals. 
Baseline information on demographics and risk factors are avail­
able for 771,659 individuals. The US screening has been done 
on 421,895 individuals. Of these, 38.5% had a diagnosed liver 
abnormality (Table 2). Approximately two­fifths were diagnosed 
with fatty liver disease and periductal fibrosis (19.7 and 17.4%, 
respectively). Only 0.5% was diagnosed with cirrhosis and 1.4% 
with liver parenchymal change. A total of 4,358 (1.0%) individu­
als were diagnosed with suspected CCA and referred for further 
investigation.
ANTiCiPATeD OUTCOMeS AND  
LONg-TeRM gOALS
On 26th December 2014, as opposed to the top down policy in 
the past, the agenda for opisthorchiasis and CCA control was 
initiated by the Cholangiocarcinoma Foundation of Thailand 
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and the National Health Security Region 8, with strong support 
by citizen groups, and passed to the National Health assembly 
where the motion was approved and endorsed by the Cabinet of 
Ministers of Thailand on 8th May 2015.
Policy implementation
On 21st June 2016, the Thai MOPH announced a decade long 
policy to eliminate OV and reduce CCA. The vision is for Thai 
citizens to be safe from OV and CCA and to have a better quality 
of life. It encourages preventive behavior, and the risk groups 
for CCA are provided with adequate and holistic medical care 
until cure or final stage disease. A set of strategic plans was laid 
down to cover activity related to: (1) intensive surveillance of OV 
and CCA, (2) strengthening preventive strategies in Thailand 
and neighboring countries, (3) enhancing screening, care, and 
referral systems, (4) supporting and facilitating community and 
local authority participation in the prevention and management 
of OV and CCA, and (5) strengthening research and development 
for efficient comprehensive data base management. As a result of 
these plans, the cumulative targets over the next 10 years for OV 
screening and treatment are >4 million, US screening >5 mil­
lion, and up to 15,000 cases for surgical treatment. Based on the 
number of CCA victims/year, the cumulative numbers for CCA 
surgery and treatment are clearly less than the annual number 
of CCA cases. However, the initiative is expected to create an 
environment stimulating a more concerted effort and willingness 
of all parties concerned to move forward in a desirable direction.
Social Participation and Mobilization: 
Cholangiocarcinoma Advocacy via the 
Cholangiocarcinoma Foundation of 
Thailand
Since 1950 government­driven programs have been carried out 
across Thailand to combat liver fluke infection based on para­
sitic disease control and cure. However, these have had only 
limited success in reducing the incidence of OV infection, and 
subsequently CCA. Moreover, some disadvantaged patients have 
no access to healthcare. Therefore, the Cholangiocarcinoma 
Foundation of Thailand was established on the 28th of September 
2012 with the aim of mobilizing the public sector directly in the 
fight to prevent and cure CCA and to save millions of lives.
Khon Kaen University is centrally located in the endemic 
area with the highest incidence of CCA worldwide. The Faculty 
of Medicine provides the underlying foundation, personnel, and 
infrastructure for the Cholangiocarcinoma Research Institute, 
the CASCAP, the CCA Center of Excellence, which provides 
diagnostic and clinical services to CCA patients, as well as the 
Cholangiocarcinoma Foundation of Thailand. These interdisci­
plinary centers help to facilitate research preclinically and clini­
cally and serve as specialty care centers for patients at risk of or 
suffering from CCA.
Model and Area expansion
Health problems consist of multiple causes and are multidimen­
sional. The CCA screening program is also active in diagnosing 
diabetes, hypertension, kidney and additional liver diseases, etc. 
Thus, the CACAP model, with its strong population data based 
software, can also serve as a basis for non­communicable disease 
control, for example, the diagnosis of chronic kidney diseases, in 
northeast Thailand. A similar extension can be made for diabetes, 
hypertension, and heart disease.
The current global community is involved in population move­
ment and migration, including borderless economic com mu nities 
such as ASEAN, leading to transborder disease movement. The suc­
cess of OV and CCA control within a single country, Thailand, can 
never be ensured without the close collaboration of the neighboring 
countries where OV is endemic: Lao PDR, Cambodia, and Vietnam. 
The CASCAP model can and should be extended to these countries.
CONCLUSiON AND FUTURe gOALS
Carcinogenesis leading to CCA development takes a considerable 
time (potentially many years and likely decades) after liver fluke 
infection. Many advances have been made in the past 20 years 
toward understanding parasite population biology, epidemiol­
ogy, and control, as well as pathogenesis and eventual cholan­
giocarcinogenesis. The prevalence and intensity of OV infection 
has shown some reduction due to control activities and improved 
sanitary conditions, but CCA incidence remains more or less 
unchanged. This may simply reflect a lack of priority. With the 
massive mortality that it causes, a comprehensive and multidis­
ciplinary control approach is required. The CASCAP model has 
been successfully used to tackle primary, secondary, and tertiary 
care with a huge data base deriving from the Isan cohort. There 
has also been a substantial role played by non­government/charity 
organizations. In particular, since OV control and reduction of 
CCA incidence takes time, the challenge is to reduce the risk of 
CCA in the threatened population. The best way is to stop expo­
sure to OV infection and the creation of a fluke­free generation. 
Indeed, it is likely that until the young, fluke­free generation has 
replaced the current middle­aged generation, CCA will continue 
to be a problem. In addition to government policy and support, 
social awareness is fundamental for control momentum and sus­
tainability, such that OV and CCA are perceived as everybody’s 
problem.
Because of the uniqueness of the CCA etiology in Southeast 
Asia, which differs markedly from that of Western countries, new 
and specific research ventures are required to battle the disease. 
An urgent and badly needed research outcome is to facilitate the 
screening of the risk population to OV, as well as to CCA. While 
robust biomarkers for OV screening, i.e., the urine assay, have made 
initial inroads, similar biomarkers for CCA are being discovered. An 
additional research dimension is to expand and modify the control 
program into nearby countries where OV is endemic, such that com­
prehensive and concerted efforts can be made toward the programs 
long­term goals, and a future fluke­free generation will be a reality.
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